AAPL   378.09 (+1.13%)
FB   244.91 (+1.92%)
GOOGL   1,517.48 (+1.19%)
AMZN   3,046.57 (-0.34%)
NVDA   399.80 (+1.58%)
MU   50.27 (-1.30%)
GE   6.82 (-2.57%)
TSLA   1,375.16 (+0.26%)
ACB   12.08 (-0.82%)
GILD   76.55 (-0.27%)
AAPL   378.09 (+1.13%)
FB   244.91 (+1.92%)
GOOGL   1,517.48 (+1.19%)
AMZN   3,046.57 (-0.34%)
NVDA   399.80 (+1.58%)
MU   50.27 (-1.30%)
GE   6.82 (-2.57%)
TSLA   1,375.16 (+0.26%)
ACB   12.08 (-0.82%)
GILD   76.55 (-0.27%)
AAPL   378.09 (+1.13%)
FB   244.91 (+1.92%)
GOOGL   1,517.48 (+1.19%)
AMZN   3,046.57 (-0.34%)
NVDA   399.80 (+1.58%)
MU   50.27 (-1.30%)
GE   6.82 (-2.57%)
TSLA   1,375.16 (+0.26%)
ACB   12.08 (-0.82%)
GILD   76.55 (-0.27%)
AAPL   378.09 (+1.13%)
FB   244.91 (+1.92%)
GOOGL   1,517.48 (+1.19%)
AMZN   3,046.57 (-0.34%)
NVDA   399.80 (+1.58%)
MU   50.27 (-1.30%)
GE   6.82 (-2.57%)
TSLA   1,375.16 (+0.26%)
ACB   12.08 (-0.82%)
GILD   76.55 (-0.27%)
Log in

NASDAQ:OPRXOptimizeRx Stock Price, Forecast & News

$14.71
+1.28 (+9.53 %)
(As of 07/7/2020 10:22 AM ET)
Add
Compare
Today's Range
$13.90
Now: $14.71
$15.09
50-Day Range
$9.91
MA: $12.33
$13.69
52-Week Range
$6.50
Now: $14.71
$17.24
Volume74,839 shs
Average Volume157,434 shs
Market Capitalization$215.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.31
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6558

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.60 million
Book Value$3.17 per share

Profitability

Net Income$-3,140,000.00

Miscellaneous

Employees37
Market Cap$215.50 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

How has OptimizeRx's stock been impacted by COVID-19 (Coronavirus)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPRX shares have increased by 95.9% and is now trading at $14.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OptimizeRx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OptimizeRx.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for OptimizeRx.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) released its quarterly earnings results on Monday, May, 4th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The company had revenue of $7.59 million for the quarter, compared to analysts' expectations of $7.10 million. OptimizeRx had a negative return on equity of 11.18% and a negative net margin of 19.86%. View OptimizeRx's earnings history.

What price target have analysts set for OPRX?

3 equities research analysts have issued 1-year price targets for OptimizeRx's shares. Their forecasts range from $17.00 to $22.00. On average, they expect OptimizeRx's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View analysts' price targets for OptimizeRx.

Has OptimizeRx been receiving favorable news coverage?

Press coverage about OPRX stock has trended negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. OptimizeRx earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about OptimizeRx.

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), NVIDIA (NVDA), Stag Industrial (STAG), Amgen (AMGN), Verizon Communications (VZ), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Etsy (ETSY) and Exelixis (EXEL).

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 50)
  • Ms. Miriam J. Paramore, Pres (Age 56)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
  • Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
  • Mr. James Brooks, Consultant (Age 50)

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $14.71.

How big of a company is OptimizeRx?

OptimizeRx has a market capitalization of $215.50 million and generates $24.60 million in revenue each year. The company earns $-3,140,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. OptimizeRx employs 37 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6558 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.